NeuroMetrix plans to add artificial intelligence to the latest iteration of its Quell transcutaneous electrical nerve stimulation (TENS) device.
AI will allow Quell 2.0 to tailor treatment to each individual user, according to the Waltham, Mass.–based based company.
Launched in September 2018 Quell 2.0 is 50% smaller and 20% more powerful than the original Quell, which debuted in 2015. Quell is worn on the leg regardless of the site of pain and is designed to send neural pulses to the brain that trigger a natural pain relief response in the central nervous system. Patients control the device and track their pain using a smartphone app. Quell 2.0 is available over-the-counter for about $300.
So how could AI help patients who use the device? NeuroMetrix chief commercial officer Frank McGillin recently discussed the decision to use AI and the future of Quell with our sister site Medical Design & Outsourcing.
The post How NeuroMetrix seeks to better relieve pain with AI appeared first on MassDevice.